Lancellotti P, Musumeci L, Jacques N, Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram-positive bacteria. JAMA Cardiol. 2019; 4 (6): 596-599. doi: 10.1001/jamacardio.2019.1189 31066863
Thomas MR, Outteridge SN, Ajjan RA, Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol. 2015; 35 (12): 2562-2570. doi: 10.1161/ATVBAHA.115.306528 26515417
Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009; 30 (16): 1964-1977. doi: 10.1093/eurheartj/ehp296 19633016
Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol. 2014; 12 (6): 426-437. doi: 10.1038/nrmicro3269 24830471
Trier DA, Gank KD, Kupferwasser D, Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun. 2008; 76 (12): 5706-5713. doi: 10.1128/IAI.00935-08 18824536
